Search results
Results From The WOW.Com Content Network
This is a list of investigational autism and pervasive developmental disorder drugs, or drugs that are currently under development for clinical use in the treatment of autistic spectrum disorders and/or other pervasive developmental disorders but are not yet approved.
In humans, tolerance to the anticonvulsant effects of clobazam may occur [27] and withdrawal seizures may occur during abrupt or over-rapid withdrawal. [ 28 ] Clobazam as with other benzodiazepine drugs can lead to physical dependence , addiction , and what is known as the benzodiazepine withdrawal syndrome .
Anticonvulsants suppress the excessive rapid firing of neurons during seizures. [6] Anticonvulsants also prevent the spread of the seizure within the brain. [7] Conventional antiepileptic drugs may block sodium channels or enhance γ-aminobutyric acid function. Several antiepileptic drugs have multiple or uncertain mechanisms of action. [8]
Richard E. Frye, M.D., PhD, a behavioral child neurologist in Arizona, has studied the drug in his research of experimental treatments for children with autism spectrum disorder. Read On The Fox ...
Convulsions are induced in captive animals, then high doses of anticonvulsant drugs are administered. [ 10 ] [ 11 ] [ 12 ] For example, kainic acid can lead to status epilepticus in animals as it is a cyclic analog of l-glutamate and an agonist for kainate receptors in the brain which makes it a potent neurotoxin and excitant.
Keppra (levetiracetam) – an anticonvulsant drug which is sometimes used as a mood stabilizer and has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome, anxiety disorder, and Alzheimer's disease; Klonopin – anti-anxiety and anti-epileptic medication of the benzodiazepine class
Primidone is an anticonvulsant of the barbiturate class; [7] however, its long-term effect in raising the seizure threshold is likely due to its active metabolite, phenobarbital. [10] The drug’s other active metabolite is phenylethylmalonamide (PEMA). Primidone was approved for medical use in the United States in 1954. [7]
The most common ones (more than 10% of patients) are tiredness and dizziness. Other fairly common side effects (1 to 10%) include impaired coordination, gastrointestinal disorders such as diarrhoea, nausea and vomiting, rash (1.1%), and hyponatremia (low sodium blood levels, 1.2%). [3] [9] There may also be an increased risk of suicidal ...